GE exits DIN-PACS bids to focus on private sectorGE Medical Systems early last month announced its withdrawal from the bidding process for the Defense Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) project. The move
GE Medical Systems early last month announced its withdrawal from the bidding process for the Defense Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) project. The move comes just weeks before bids are set to be awarded for the project, which some estimate to be worth $300 million to $1.25 billion.
GEMS officials say the company decided to exit the process after it was unable to meet two requirements in the project. The Milwaukee-based vendor participated throughout the benchmark testing and RFP responses, but was ultimately unsuccessful in its attempts to persuade the government to relax the requirements. Since developing those capabilities were not consistent with the company's plans for its commercial product line, GEMS made the difficult decision to withdraw, according to the firm.
In keeping with the confidential nature of the DIN-PACS bidding process, GEMS would not disclose the specific requirements it was unable to meet.
With GEMS now officially out of the running, the field has apparently narrowed to several consortia:
Although the government has not guaranteed PACS sales outside of the three projects it specified in the RFP, the real reward will come when Department of Defense hospitals look to acquire PACS technology. By one estimate, there are 123 hospitals in the network, many of which are looking to upgrade to digital image management (PNN 6/97).
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.